Skip to main content

The Roles of Pathogens in Gut-Related Diseases and the Strategies for Inhibiting Their Growth

Cover image for Research Topic "The Roles of Pathogens in Gut-Related Diseases and the Strategies for Inhibiting Their Growth"
75kviews
Editorial: The roles of pathogens in gut-related diseases and the strategies for inhibiting their growth
Editorial04 December 2024
Editorial: The roles of pathogens in gut-related diseases and the strategies for inhibiting their growth

Healthy life is inconceivable without balanced microbial communities in the gut, known as the gut microbiome (GM), which play a critical role in digestion, metabolism, immune function, and overall health (Zhang et al., 2023). These commensals are sensitive to both internal and external factors that cause dysbiosis-a condition in which the diversity and composition of GM are disturbed. This imbalance negatively affects the complex relationship between the host and its microbiome (Wu et al., 2023).During dysbiosis, opportunistic pathogens dominate the gut ecosystem, individually or collectively, triggering serious health problems such as gastrointestinal infections, ulcers, inflammation, cancer, diarrhea, obesity, and other diseases (Wu et al., 2023;Alam et al., 2024). Factors that induce dysbiosis in GM include environment, imbalanced diet, chronic diseases, infection, and medication (Fig 1).Among the medicinal treatment, antimicrobial agents induce drastic dysbiosis in the GM that trigger the emergence of opportunistic pathogens. There is growing evidence that has reported opportunistic infections supported by gut-dwelling bacteria that are commonly considered beneficial. One such bacterium is Bacteroides fragilis (normally a harmless gut inhabitant) that proliferates and cause infections after the antimicrobial therapies. Certain strains of this bacterium are linked to peritonitis and intra-abdominal abscesses (Jasemi et al., 2021). Similarly, the overgrowth of Clostridium difficile following antibiotic treatment can lead to antibiotic-associated diarrhea and, and in severe cases, can cause pseudomembranous colitis (López-Ureña et al., 2016).The overabundance of opportunistic pathogens further worsens GM dysbiosis and cause serious complications that reach beyond the gastrointestinal tract, impacting various parts of the body. For example, Streptococcus gallolyticus, a gut-resident commensal, can breach a compromised intestinal barrier, enter the bloodstream, and cause infective endocarditis in individuals with damaged heart valves (Lourenço et al., 2009). Additionally, an increased prevalence of Prevotella species, typically gut commensals, has been associated with the onset of rheumatoid arthritis (Abdelsalam et al., 2023). Likewise, Helicobacter pylori, which infects more than half of the global population and, if left untreated, can lead to chronic gastritis, cap polyposis (Lu et al., 2024), and peptic ulcer disease (Cheng et al., 2023).Realizing the importance of this growing enigma, we believed that the role of pathogens and opportunistic microbes in the onset, progression, and control of various diseases demand comprehensive attention. To gain deeper insight into the mechanisms underlying the pathogen-induced dysbiosis and its effects on host' health, we initiated a research topic to provide a collaborative platform for researchers at the forefront of this field. In response to our call for submissions, we received 25 articles, of which only nine met publication standards. In the following section of this editorial, we provide a comprehensive summary of these manuscripts, focusing on the role of pathogens in gut microbiota dysbiosis, their impact on the host, and potential strategies for pathogen control. This section also highlights the current state of knowledge and identifies key areas for future research.

Numerous studies have demonstrated that dysbiotic microbial communities disrupt the gut barrier, lead to immune imbalances, and contribute to the development of chronic metabolic diseases. Even the intake of an imbalanced diet can have profound effects on the gut microbiome. In a recent study, Sun et al. (2024) fed rats an adenine-rich diet, which resulted in reduced diversity and compositional variation of GM compared to control rats. Pathophysiological analysis of the test group revealed calcification in the kidneys and thoracic aorta. Notably, vascular calcification is a recognized risk factor for cardiovascular disease, particularly in patients with chronic kidney disease (CKD). Furthermore, an increase level of Acinetobacter was noticed in the blood of the test group which was positively associated with increase in calcification factors (such as BSP, FGF-23, and SOST), lipopolysaccharide, phosphorous, and genes involve in the mineral absorption pathway. The authors suggest that elevated level of Acinetobacter in CKD holds significant potential as both a diagnostic marker and a therapeutic target. In addition, a cluster of five bacterial species has already been proposed as non-invasive diagnostic markers for CKD (Sun et al., 2024).Similarly, during nonalcoholic steatohepatitis (a severe form of nonalcoholic fatty liver disease), dysbiotic gut microbiota compromise the intestinal barrier, leading to increased translocation of toxic metabolites into the circulatory system and triggering liver inflammation (Huang et al., 2024;(Zhu et al., 2022). Bacteria that have been found abundant in the gut of non-alcoholic liver diseases include Proteobacteria, Enterobacteria, Escherichia. Whereas, bacterial metabolites that participate in the development of non-alcoholic liver disease include amino acids, bile acids, choline and butyrate (Alam et al., 2024).

Fixing disturbed GM composition has emerged as a new strategy for treatment of diseases. Interventions focused at reinstating the GM-such as the use of probiotics, prebiotics, dietary modifications, fecal microbiota transplants, and microbial-targeted therapies-have exhibited potential beneficial role in lowering the disease symptoms, improving immune responses, and uplifting the overall health.In a recent study, Tang et al., (2024) demonstrated that balancing dysbiotic GM during psoriasis, a skin condition which is characterized by inflammation, could fix systemic inflammation and alleviate psoriasis symptoms. They successfully treated psoriasis mouse model with Shenling Baizhu Powder and concluded that fixing GM could impact lipid metabolism through reducing inflammatory mediators that conferring therapeutic abilities during psoriasis management.Similarly, Zhang et al., (2024) fixed dysbiosis through aconite, a form of anti-diarrhea Chinese medicine. Aconite promoted the growth of bacteria belonging to Clostridia, Lachnospiraceae, Muribaculaceae, Prevotellaceae, and Ruminococcus whereas, inhibited the growth of Escherichia-Shigella and Parasutterella. Another study has reported disturbed microbiome composition during sarcopenia, a state of pathological decline of muscle mass and strengthassociated with aging. They reported 29 genera with altered abundance in sarcopenia and proposed that Blautia, Lachnospiraceae, and Subdoligranulum could be developed as diagnostic markers for sarcopenia (Zhou et al., 2023).Another interventive strategy to restore GM composition and restrict potential pathogen is the use of herbal products (Dong et al., 2024). In a recent study, Litsea cubeba essential oil was found to positively affect gut microbial communities, leading to improved digestion, enhanced growth performance, increased antioxidant levels, and more efficient nutrient absorption (Cheng et al., 2023). Similarly, Artemisia argyi essential oil has demonstrated weight management effects, which may be partly explained by its ability to modulate gut microbiota composition (Wang et al., 2022).Conversely, gut bacteria also play a role in improving the absorption and effectiveness of herbal products. A recent study utilized a biotransformation-integrated network pharmacology approach to explore how gut microbiota enhances the efficacy of Astragaloside IV in treating intracerebral hemorrhage (ICH). The researchers found that GM and liver metabolism converted Astragaloside IV into metabolites with improved bioavailability and better permeability across the blood-brain barrier, thus enhancing its therapeutic potential (Hu et al., 2023).As medicine moves toward more personalized approaches, profiling an individual's gut microbiome before administering herbal products becomes increasingly important.For instance, a recent study showed that podophyllotoxin, a naturally occurring aryltetralin lignan, induces neurotoxicity via the microbiota-gut-brain axis.Podophyllotoxin exposure altered the composition of gut microbiota, increasing Escherichia-Shigella populations while reducing Lactobacillus, which elevated proinflammatory factors and disrupted kynurenine metabolism in the hippocampus. These changes may contribute to cognitive dysfunction and neurotoxicity (Duan et al., 2024).In conclusion, herbal products hold greater abilities for reinstating gut microbiome balance, which in turn can positively affect host health and alleviate disease symptoms.Herbal compounds not only stop pathogenic growth but also improve microbial diversity, improving functions such as digestion, nutrient absorption, antioxidant levels, and weight management.

GM dysbiosis has been linked to the development of various illnesses that results mainly from the overgrowth of opportunistic pathogens, which modulate mucosal homeostasis and affect distant organs such as the kidneys, heart, liver, and pancreas. Various therapeutic strategies are being developed to restore GM diversity and composition for alleviating disease symptoms and improving overall health. Among these strategies, prebiotics and probiotics target the promotion of beneficial bacteria and improve resilience against pathogenic colonization. These strategies fix dysbiotic GM which consequently treat systemic diseases that are associated with dysbiosis, thus creating the possibility for a novel field in preventative and therapeutic medicine.

2,480 views

4 citations

Global research trends on gut microbiota and metabolic dysfunction-associated steatohepatitis: Insights from bibliometric and scientometric analysis
SYSTEMATIC REVIEW
11 July 2024
Global research trends on gut microbiota and metabolic dysfunction-associated steatohepatitis: Insights from bibliometric and scientometric analysis
Naqash Alam, 6 more and Enqi Liu
Background: Metabolic dysfunction-associated steatohepatitis (MASH) is an inflammatory subtype of metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as a replacement term for NAFLD, a common, multifactorial and poorly understood liver disease whose incidence is increasing worldwide. In recent years, there has been increasing scientific interest in exploring the relationship between gut microbiota and MASH. To learn more about the gut microbiota in MASH, this study aims to provide a comprehensive analysis of the knowledge structure and research hotspots from a bibliometric perspective.We searched the Web of Science Core Collection for articles and reviews that covered the connections between gut microbiota and MASH over the last decade. The Online Analysis Platforms, VOSviewer, CiteSpace, the R tool "bibliometrix" were used to analyzed existing publications trends and hotspots.Results: A total of 4,069 documents related to the interaction between gut microbiota and MASH were retrieved from 2014 to 2023. The number of annual publications increased significantly over the last decade, particularly in the United States and China. The University of California-San Diego was the most productive institution, while researcher Rohit Loomba published the most papers in the field. Younossi ZM was ranked as the first co-cited author and largest contributor of highly cited articles in the field. Gastroenterology and hepatology were the most common specialty category. The most cited journal in the last decade was Hepatology. The Keyword Bursts analysis highlighted the importance of studying the association between gut microbiota and MASH, as well as related factors such as metabolic syndrome, insulin resistance, endotoxemia and overgrowth of gut bacteria. Keyword clusters with co-citation were used to illustrate important topics including intestinal permeability, insulin sensitivity and liver immunology. The most common keywords include insulin resistance, obesity, dysbiosis, inflammation and oxidative stress, which are current hotspots.Our analysis highlights key aspects of this field and emphasizes multiorgan crosstalk in MASLD/MASH pathogenesis. In particular, the central role of the gut-liver axis and the significant influence of gut microbiota dysbiosis on disease progression are highlighted. Furthermore, our results highlight the transformative potential of microbiota-specific therapies and cover the way for innovative healthcare and pharmaceutical strategies.

5,918 views

13 citations

ORIGINAL RESEARCH
14 February 2024
Network pharmacology and gut microbiota insights: unraveling Shenling Baizhu powder’s role in psoriasis treatment
Bin Tang, 8 more and Chuanjian Lu

6,700 views

17 citations

ORIGINAL RESEARCH
5 January 2024
Role of symbiotic microbiota dysbiosis in the progression of chronic kidney disease accompanied with vascular calcification
Mengying Sun, 5 more and Rui Zhang

4,296 views

14 citations

CLINICAL TRIAL
7 November 2023
Efficacy and safety of high-dose ilaprazole-amoxicillin dual therapy for Helicobacter pylori eradication: a prospective, single-center, randomized trial
Jianping Cheng, 9 more and Haiou Ding

4,204 views

9 citations

ORIGINAL RESEARCH
9 May 2024
Clinical, endoscopic, pathological characteristics and management of cap polyposis: experience from a Tertiary Hospital in China
Yi Lu, 3 more and Jiachen Sun

2,715 views

3 citations

Characteristics of the gut microbiome and metabolic profile in elderly patients with sarcopenia
ORIGINAL RESEARCH
3 November 2023
Characteristics of the gut microbiome and metabolic profile in elderly patients with sarcopenia
Jing Zhou, 8 more and Lishu Xu
There is growing evidence of research indicating that the gut microbiota is involved in the development of sarcopenia. Nevertheless, there exists a notable deficiency in comprehension concerning the connection between irregularities in the intestinal microbiome and metabolic processes in older individuals suffering from sarcopenia. To analyze fecal samples obtained from a cohort of 30 older patients diagnosed with sarcopenia as well as 30 older patients without sarcopenia, this study employed 16S rDNA sequencing and liquid chromatography-mass spectrometry (LC-MS)based non-targeted metabolomics profiling techniques. As a result, we found that 29 genera and 172 metabolites were significantly altered in the sarcopenic patients. Among them, Blautia, Lachnospiraceae_unclassified, and Subdoligranulum were the bacteria with a potential diagnostic value for sarcopenia diagnosis. Correlation analysis between clinical indices and these gut bacteria suggested that the IL-6 level was negatively correlated with Blautia. Function prediction analysis demonstrated that 17 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways differ significantly between sarcopenic and non-sarcopenic patients. The primary classes of metabolites identified in the study included lipids and lipid-like molecules, organic acids and derivatives, and organoheterocyclic compounds. KEGG enrichment analysis showed that purine metabolism, arginine and proline metabolism, alanine, aspartate, and glutamate metabolism, butanoate metabolism, and histidine metabolism may contribute to the development of sarcopenia. The correlation study on gut microbiota and metabolites found that Lachnospiraceae_unclassified was positively associated with seven metabolites that were more abundant in the non-sarcopenia group and negatively correlated with three metabolites that were more abundant in the sarcopenia group. In addition, Subdoligranulum was positively correlated with seven metabolites that were lacking in sarcopenia and negatively correlated with two metabolites that were enriching in sarcopenia. Moreover, Blautia was positively associated with xanthosine. We conducted a study on the intestinal microbiota and metabolic profile of elderly individuals with sarcopenia, offering a comprehensive analysis of the overall ecosystem. Through this investigation, we were able to validate existing research on the gutmuscle axis and further investigate potential pathogenic processes and treatment options for sarcopenia.

6,917 views

41 citations

Ameliorative effect of Aconite aqueous extract on diarrhea is associated with modulation of the gut microbiota and bile acid metabolism
ORIGINAL RESEARCH
17 May 2023
Ameliorative effect of Aconite aqueous extract on diarrhea is associated with modulation of the gut microbiota and bile acid metabolism
Dandan Zhang, 6 more and Cheng Peng
Introduction: Aconite is a traditional Chinese medicine (TCM) that is widely used to treat diarrhea for thousands of years. However, it is not clear whether the antidiarrheal role of Aconite aqueous extract (AA) is associated with regulating gut microbiota and bile acids (BAs) metabolism. The experiment was conducted to confirm whether AA can exert its antidiarrheal effects by regulating gut microbiota and BA metabolism. Methods: The therapeutic effect of AA on diarrhea was measured by body weight, fecal water content, diarrhea scores, intestinal propulsion rate, colonic pathology, and colonic immunohistochemistry. In addition, 16S rRNA high-throughput sequencing was used to analyze the effect of AA on gut microbiota, and targeted metabolomics was used for analyzing the effect of AA on BAs metabolism. Results: The results showed that AA could reduce fecal water content and diarrhea score, inhibit intestinal propulsion rate and colon pathological changes, and increase AQP3 and AQP4 in the colon. In addition, AA can regulate gut microbiota, including increasing gut microbiota richness (Ace and Chao index), altering gut microbiota community structure (PCA, PCoA, and NMDS), increasing the relative abundance of norank_f_Muribaculaceae, Ruminococcus, Lachnospiraceae_NK4A136_group, Prevotellaceae_UCG-001, and norank_f_norank_o_Clostridia_UCG-014, and decreasing the relative abundance of Escherichia-Shigella, unclassified_f_Ruminococcaceae, Ruminococcus_torques_group, and Parasutterella. More importantly, AA can significantly increase fecal primary BAs TCA, and secondary BAs DCA, LCA, GDCA, dehydro-LCA, and 12-keto-LCA to restore BAs’ homeostasis. Also, AA increased the ratio of DCA/CA, DCA/TCA, and LCA/CDCA, and decreased the ratio of TLCA/LCA, GLCA/LCA, and TUDCA/UDCA. Conclusion: The antidiarrheal role of AA is associated with the restoration of gut microbiota and BA metabolism-related homeostasis. This study provides insights into the application of AA and the treatment of diarrhea.

4,815 views

24 citations

REVIEW
23 August 2023
The role of gut microbiota and drug interactions in the development of colorectal cancer
Jinna Wu, 3 more and Chenglai Xia

5,017 views

12 citations